In a major breakthrough, India’s first mRNA-based COVID vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trails. This was informed by the Department of Biotechnology (DBT) on Tuesday. As per reports, the Pune-based biotechnology company had submitted the interim clinical data of the vaccine’s Phase 1 study to the Central Drugs Standard Control Organisation (CDSCO).

New Delhi, Aug 24 (PTI) India''s first mRNA-based COVID-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trails, the Department of Biotechnology (DBT) said on Tuesday.

The Pune-based biotechnology company had submitted the interim clinical data of the vaccine''s Phase 1 study to the Central Drugs Standard Control Organisation (CDSCO), it said.…

BENGALURU: Indian pharmaceutical firm Gennova Biopharmaceuticals' COVID-19 vaccine, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said on Tuesday.

Government authorities have also approved further studies to test the vaccine's efficacy in a larger population. Gennova plans to conduct a mid-stage study at about 10 to 15 sites and a late-stage trial at 22 to 27 sites in India.…

Women professionals in white-collar roles in India are not comfortable talking about their health issues due to the prevailing biases, stigmas and misperceptions, according to a recent study conducted by Emcure Pharmaceuticals in association with Ipsos Research (Ipsos India).

The Indian Women’s Health Report, which surveyed 1000 working women aged between 25 to 55 years in white-collar jobs across seven cities ((Bangalore, Chennai, Delhi, Hyderabad, Kolkata, Mumbai and Pune),…

India’s apex drug regulator on Tuesday approved the phase 2 and 3 clinical trials of Covid vaccine candidate by Pune-based Gennova, which has shown very encouraging results in the early-stage trials.

Importantly, this mRNA-based vaccine will likely be compared with Covishiled, and not placebo while the trials will include about 4,400 participants at 22-24 sites across the country. Also, it may be the first vaccine to be introduced in India specifically designed against the delta…

Gennova Biopharmaceuticals' COVID-19 vaccine has been found to be safe and effective in an early-stage study, according to India's drug regulator.

The company has been allowed to conduct further studies to test efficacy and other parameters. The Maharashtra-based pharmaceutical company plans to conduct a late stage trial at close to 25 sites in the country.…

Gennova Biopharmaceuticals, the Pune-based biotechnology company which is developing India's first mRNA-based COVID-19 vaccine HGCO19, on August 24 received approval from the Drug Controller General of India (DCGI) to conduct Phase 2 and Phase 3 clinical trials.

Gennova submitted the proposed Phase II and Phase III study titled 'A Prospective, Multicentre, Randomised, Active-controlled, Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the Safety,…

Effective Treatment for Hair Fall at Home চুল পড়া বন্ধ করতে নারকেল তেলের সঙ্গে শুধু এই জিনিসটা মিশিয়ে লাগাও আর রেজাল্ট দেখো

Let’s talk about the Effective treatments for hair fall at home to stop hair loss naturally.

What is the most effective treatment for hair fall at home? What is the best natural treatment for hair fall at home? What is the best treatment for hair fall? Do these hair fall treatments even work? Will this treatment stop my hair fall immediately? How expensive…

India's first and only mRNA vaccine against Covid-19 on Tuesday received regulatory approval for advanced clinical trials to examine its protective efficacy, raising the hopes of its availability for public use after a few months.

“It is a matter of pride that Nation’s first mRNA-based vaccine is found to be safe and the Drugs Controller General of India has approved the phase II/III trial. This is an important milestone in our indigenous vaccine development mission and positions…

India's first mRNA vaccine HGCO19 received DCGI nod for Phase II/III clinical trials on Tuesday. The Covid-19 vaccine has been developed by Gennova Biopharmaceuticals Ltd, a Pune-based biotechnology company in partnership with the Department of Biotechnology.

Read more at…

BENGALURU, Aug 19 (Reuters) – India's Emcure Pharmaceuticals has filed draft papers with the market regulator for an initial public offering, which a source with direct knowledge of the matter said could be worth up to 50 billion rupees ($671.89 million).

Emcure is the latest Indian company to tap capital markets this year in a fund-raising frenzy driven by abundant liquidity and record-high stock markets.

Read more at…

India's first homegrown mRNA-based COVID-19 vaccine, being developed by Gennova Biopharmaceuticals, has been approved for further clinical trials today after the shot was found to be safe and effective in an early-stage study.

India has also authorised emergency use for two domestically developed COVID-19 shots, made by Bharat Biotech and Zydus Cadila, but does not have mRNA-based vaccines yet in its immunisation programme ahead of a potential third coronavirus wave.

Read more at…

Developed by Gennova Biopharmaceuticals Ltd, the Pune-based biotechnology company, its interim clinical data of the Phase I were submitted to the Central Drugs Standard Control Organisation (CDSCO) for review.

Dr Sanjay Singh, CEO of Gennova Biopharmaceuticals Ltd said, “After establishing the safety of our mRNA-based COVID-19 vaccine candidate HGCO19 in Phase I clinical trial, Gennova’s focus is to start Phase II/III pivotal clinical trial. In parallel, Gennova is investing in…

BENGALURU (Reuters) -India's Emcure Pharmaceuticals has filed draft papers with the market regulator for an initial public offering, which a source with direct knowledge of the matter said could be worth up to 50 billion rupees ($671.89 million).

Emcure is the latest Indian company to tap capital markets this year in a fund-raising frenzy driven by abundant liquidity and record-high stock markets.

Read more at…

Indian pharmaceutical firm Gennova Biopharmaceuticals` COVID-19 vaccine, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said on Tuesday (August 24).

Government authorities have also approved further studies to test the vaccine`s efficacy in a larger population. Gennova plans to conduct a mid-stage study at about 10 to 15 sites and a late-stage trial at 22 to 27 sites in India.

Read more at…

The Enforcement Directorate and the Central Investigation Agency (CBI) have stepped up their efforts to nab the accused in the alleged bribery scam of Rs 3,600 crore in the AgustaWestland scam. A source familiar with the whole matter told this to Hindustan Times. ED raids on Wednesday at the premises of realty firm MGF MD Shravan Gupta were conducted to trace the same bribe money that went to several companies during a given period of time.

Read more at…

Bain Capital-backed Emcure Pharmaceuticals has filed preliminary papers with capital markets regulator Sebi to raise funds through an initial share sale.The initial public offering IPO comprises fresh issuance of equity shares worth Rs 1,100 crore and an offer of sale of 18,168,356 shares by promoters and existing shareholders, according to the draft red herring prospectus DRHP.As a part of the OFS, promoters Satish Mehta and Sunil Mehta will offload 20.30 lakh and 2.5 lakh shares,…

Pune-based Emcure Pharmaceuticals is bullish about scientific innovation and its next big bet is mRNA vaccines for COVID-19, the company's Founder and MD Satish Mehta told YourStory.

“We are working on it (mRNA vaccines), and it will be absolutely comparable to the Pfizer and Moderna vaccines,” Emcure MD Satish Mehta told YourStory Founder Shradha Sharma in an interview.

Read More at…

The Centre on Tuesday informed that the country's first mRNA-based Covid vaccine was found to be safe, and was given go ahead for Phase II/III trials.

Gennova Biopharmaceuticals, the Pune-based biotechnology company, working on the nation's first mRNA-based Covid vaccine, submitted the interim clinical data of the Phase-I study to the Central Drugs Standard Control Organisation (CDSCO), the government's National Regulatory Authority (NRA).

Read more at…

In July 2020, the company had filed a complaint with the Gurugram Police Commissioner following which an investigation was carried out by the EOW and a case was registered at the DLF Phase-1 police station.

According to the FIR, Shravan Gupta is accused of causing a loss of about Rs 182.48 crore to the company through illegal land deals based on fake documents.

Emaar had stepped into the Indian real estate sector in 2005 through Foreign Direct Investment (FDI) and bought land…